Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors

Steve McGaraughty, Marlon Cowart, Michael F. Jarvis, Robert F Berman

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Adenosine (ADO) acts as an inhibitory neuromodulator throughout the central and peripheral nervous system and can regulate seizure and nociceptive activity. However, the positive actions of systemically administered ADO are usually accompanied by undesirable side effects such as hypomobility and cardio-suppression. Adenosine kinase (AK) is the primary metabolic enzyme regulating intra- and extracellular concentrations of ADO. We review the recent development of structurally novel nucleoside and nonnucleoside AK inhibitors that demonstrate high specificity for the AK enzyme. Several of these compounds have shown significant beneficial effects in animal models of epilepsy and pain with an improved preclinical therapeutic window over direct acting ADO receptor agonists.

Original languageEnglish (US)
Pages (from-to)43-58
Number of pages16
JournalCurrent Topics in Medicinal Chemistry
Volume5
Issue number1
DOIs
StatePublished - 2005

Fingerprint

Adenosine Kinase
Anticonvulsants
Adenosine
Purinergic P1 Receptor Agonists
Peripheral Nervous System
Neurology
Enzymes
Nucleosides
Neurotransmitter Agents
Epilepsy
Animals
Seizures
Central Nervous System
Animal Models
Pain
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Chemistry(all)

Cite this

Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. / McGaraughty, Steve; Cowart, Marlon; Jarvis, Michael F.; Berman, Robert F.

In: Current Topics in Medicinal Chemistry, Vol. 5, No. 1, 2005, p. 43-58.

Research output: Contribution to journalArticle

McGaraughty, Steve ; Cowart, Marlon ; Jarvis, Michael F. ; Berman, Robert F. / Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. In: Current Topics in Medicinal Chemistry. 2005 ; Vol. 5, No. 1. pp. 43-58.
@article{588e41b979f7408899156a7b23261f8b,
title = "Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors",
abstract = "Adenosine (ADO) acts as an inhibitory neuromodulator throughout the central and peripheral nervous system and can regulate seizure and nociceptive activity. However, the positive actions of systemically administered ADO are usually accompanied by undesirable side effects such as hypomobility and cardio-suppression. Adenosine kinase (AK) is the primary metabolic enzyme regulating intra- and extracellular concentrations of ADO. We review the recent development of structurally novel nucleoside and nonnucleoside AK inhibitors that demonstrate high specificity for the AK enzyme. Several of these compounds have shown significant beneficial effects in animal models of epilepsy and pain with an improved preclinical therapeutic window over direct acting ADO receptor agonists.",
author = "Steve McGaraughty and Marlon Cowart and Jarvis, {Michael F.} and Berman, {Robert F}",
year = "2005",
doi = "10.2174/1568026053386845",
language = "English (US)",
volume = "5",
pages = "43--58",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors

AU - McGaraughty, Steve

AU - Cowart, Marlon

AU - Jarvis, Michael F.

AU - Berman, Robert F

PY - 2005

Y1 - 2005

N2 - Adenosine (ADO) acts as an inhibitory neuromodulator throughout the central and peripheral nervous system and can regulate seizure and nociceptive activity. However, the positive actions of systemically administered ADO are usually accompanied by undesirable side effects such as hypomobility and cardio-suppression. Adenosine kinase (AK) is the primary metabolic enzyme regulating intra- and extracellular concentrations of ADO. We review the recent development of structurally novel nucleoside and nonnucleoside AK inhibitors that demonstrate high specificity for the AK enzyme. Several of these compounds have shown significant beneficial effects in animal models of epilepsy and pain with an improved preclinical therapeutic window over direct acting ADO receptor agonists.

AB - Adenosine (ADO) acts as an inhibitory neuromodulator throughout the central and peripheral nervous system and can regulate seizure and nociceptive activity. However, the positive actions of systemically administered ADO are usually accompanied by undesirable side effects such as hypomobility and cardio-suppression. Adenosine kinase (AK) is the primary metabolic enzyme regulating intra- and extracellular concentrations of ADO. We review the recent development of structurally novel nucleoside and nonnucleoside AK inhibitors that demonstrate high specificity for the AK enzyme. Several of these compounds have shown significant beneficial effects in animal models of epilepsy and pain with an improved preclinical therapeutic window over direct acting ADO receptor agonists.

UR - http://www.scopus.com/inward/record.url?scp=13444273445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444273445&partnerID=8YFLogxK

U2 - 10.2174/1568026053386845

DO - 10.2174/1568026053386845

M3 - Article

VL - 5

SP - 43

EP - 58

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 1

ER -